These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 33923688)

  • 1. The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery.
    Gagliardi M; Ashizawa AT
    Biomedicines; 2021 Apr; 9(4):. PubMed ID: 33923688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense oligonucleotide-based therapies for the treatment of osteoarthritis: Opportunities and roadblocks.
    Nakamura A; Ali SA; Kapoor M
    Bone; 2020 Sep; 138():115461. PubMed ID: 32485363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Versatility of Liposomes for Antisense Oligonucleotide Delivery: A Special Focus on Various Therapeutic Areas.
    Gupta R; Salave S; Rana D; Karunakaran B; Butreddy A; Benival D; Kommineni N
    Pharmaceutics; 2023 May; 15(5):. PubMed ID: 37242677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Status of Antisense Oligonucleotide-Based Therapy in Neuromuscular Disorders.
    Bizot F; Vulin A; Goyenvalle A
    Drugs; 2020 Sep; 80(14):1397-1415. PubMed ID: 32696107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development.
    Dhuri K; Bechtold C; Quijano E; Pham H; Gupta A; Vikram A; Bahal R
    J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32604776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overcoming the challenges of tissue delivery for oligonucleotide therapeutics.
    Gökirmak T; Nikan M; Wiechmann S; Prakash TP; Tanowitz M; Seth PP
    Trends Pharmacol Sci; 2021 Jul; 42(7):588-604. PubMed ID: 34020790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug Discovery Perspectives of Antisense Oligonucleotides.
    Kim Y
    Biomol Ther (Seoul); 2023 May; 31(3):241-252. PubMed ID: 36859811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicology of antisense therapeutics.
    Jason TL; Koropatnick J; Berg RW
    Toxicol Appl Pharmacol; 2004 Nov; 201(1):66-83. PubMed ID: 15519609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medicinal Chemistry of Antisense Oligonucleotides for Therapeutic Use in SARS-CoV-2: Design Strategies and Challenges for Targeted Delivery.
    Nedaeinia R; Ranjbar M; Goli M; Etebari M; Safabakhsh S; Bayram H; Ferns GA; Tehrani HM; Salehi R
    Curr Med Chem; 2024 Jun; ():. PubMed ID: 38860908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. iRGD-liposomes enhance tumor delivery and therapeutic efficacy of antisense oligonucleotide drugs against primary prostate cancer and bone metastasis.
    Guan J; Guo H; Tang T; Wang Y; Wei Y; Seth P; Li Y; Dehm SM; Ruoslahti E; Pang HB
    Adv Funct Mater; 2021 Jun; 31(24):. PubMed ID: 34211360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Use of Tricyclo-DNA Oligomers for the Treatment of Genetic Disorders.
    Aupy P; Echevarría L; Relizani K; Goyenvalle A
    Biomedicines; 2017 Dec; 6(1):. PubMed ID: 29271929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances and Challenges of Liposome Assisted Drug Delivery.
    Sercombe L; Veerati T; Moheimani F; Wu SY; Sood AK; Hua S
    Front Pharmacol; 2015; 6():286. PubMed ID: 26648870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisense oligonucleotides for the treatment of dyslipidaemia.
    Visser ME; Witztum JL; Stroes ES; Kastelein JJ
    Eur Heart J; 2012 Jun; 33(12):1451-8. PubMed ID: 22634577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
    Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN
    Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders.
    Silva AC; Lobo DD; Martins IM; Lopes SM; Henriques C; Duarte SP; Dodart JC; Nobre RJ; Pereira de Almeida L
    Brain; 2020 Feb; 143(2):407-429. PubMed ID: 31738395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel integrated strategy (full length gene targeting) for mRNA accessible site tagging combined with microarray hybridization/RNase H cleavage to screen effective antisense oligonucleotides.
    Sun Y; Duan M; Lin R; Wang D; Li C; Bo X; Wang S
    Mol Vis; 2006 Nov; 12():1364-71. PubMed ID: 17149362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced Antisense Oligonucleotide Delivery Using Cationic Liposomes Grafted with Trastuzumab: A Proof-of-Concept Study in Prostate Cancer.
    Sicard G; Paris C; Giacometti S; Rodallec A; Ciccolini J; Rocchi P; Fanciullino R
    Pharmaceutics; 2020 Nov; 12(12):. PubMed ID: 33260460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Making sense of therapeutics using antisense technology.
    Malik R; Roy I
    Expert Opin Drug Discov; 2011 May; 6(5):507-26. PubMed ID: 22646076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated Assessment of the Clinical Performance of GalNAc
    Crooke ST; Baker BF; Xia S; Yu RZ; Viney NJ; Wang Y; Tsimikas S; Geary RS
    Nucleic Acid Ther; 2019 Feb; 29(1):16-32. PubMed ID: 30570431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
    Kashyap AS; Thelemann T; Klar R; Kallert SM; Festag J; Buchi M; Hinterwimmer L; Schell M; Michel S; Jaschinski F; Zippelius A
    J Immunother Cancer; 2019 Mar; 7(1):67. PubMed ID: 30871609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.